Evaluation and treatment of acute ischemic syndromes, in the heart and brain, require vessel visualization by iodinated X-ray contrast agents. However, these contrast agents can induce injury, in both the kidneys and target organs themselves. Sulfobutylether beta cyclodextrin (SBECD) added to iohexol (SBECD-iohexol) (Captisol Enabled-iohexol, Ligand Pharmaceuticals, Inc, San Diego, CA) is currently in clinical trials in cardiovascular procedures, to determine its relative renal safety in high-risk patients. Preclinical studies showed that SBECD-iohexol reduced contrast-induced acute kidney injury in rodent models by blocking apoptosis. The current study was undertaken to determine whether SBECD-iohexol is also cardioprotective, in the male rat ischemia-reperfusion model, compared to iohexol alone.

中文翻译：

---

一种具有心脏保护作用的肾保护性碘化造影剂：一项初步研究

心脏和大脑急性缺血综合征的评估和治疗需要通过碘化 X 射线造影剂进行血管可视化。然而，这些造影剂会在肾脏和目标器官本身中引起损伤。磺丁基醚β环糊精 (SBECD) 添加到碘海醇 (SBECD-iohexol)（Captisol Enabled-iohexol, Ligand Pharmaceuticals, Inc, San Diego, CA）目前正在进行心血管手术的临床试验，以确定其在高危患者中的相对肾脏安全性. 临床前研究表明，SBECD-iohexol 通过阻断细胞凋亡减少啮齿动物模型中造影剂引起的急性肾损伤。目前的研究旨在确定与单独使用碘海醇相比，SBECD-碘海醇在雄性大鼠缺血再灌注模型中是否也具有心脏保护作用。